<DOC>
	<DOCNO>NCT02452008</DOCNO>
	<brief_summary>The primary objective study compare progression free survival ( PFS ) patient metastatic castration-resistant prostate cancer treat enzalutamide combination LY2157299 ( Arm 1 ) versus enzalutamide alone ( Arm 2 ) .</brief_summary>
	<brief_title>Study TGF-β Receptor Inhibitor Galunisertib ( LY2157299 ) Enzalutamide Metastatic Castration-resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Have metastatic castrationresistant prostate cancer Must prior abiraterone treatment Life expectancy great 3 month ECOG performance status 0 2 Age ≥18 year Have measurable disease Patients acceptance tumor biopsy accessible lesion baseline treatment lesion biopsied acceptable clinical risk ( judged investigator ) . Ability take oral medication Patients must adequate organ marrow function define studyspecified laboratory test Must use acceptable form birth control study Ability understand willingness sign write informed consent document Known history evidence brain metastasis Prior chemotherapy metastatic disease castrationresistant prostate cancer Had surgery within 4 week prior first dose study drug Had radiation , biological , investigational cancer therapy within 2 week prior first dose study drug Had secondline hormonal therapy within 2 week prior first dose study drug Systemic steroid within 1 week prior first dose study drug Had prior enzalutamide , ARN509 , galeterone therapy Have moderate severe cardiovascular disease Have history seizure Have uncontrolled intercurrent illness , include limited ongoing active infection , systematic congestive heart failure , unstable angina pectoris , cardiac arrhythmia psychiatric condition would limit compliance study requirement Have history autoimmune disease : inflammatory bowel disease , ( include ulcerative colitis Crohn 's Disease ) , rheumatoid arthritis , systemic progressive sclerosis ( scleroderma ) , systemic lupus erythmatosus ( SLE ) autoimmune vasculitis ( e.g. , Wegener 's Granulomatosis ) , CNS motor neuropathy consider autoimmune origin ( e.g. , GuillianBarre Syndrome , Myasthenia Gravis , Multiple Sclerosis ) Have know history infection HIV , hepatitis B , hepatitis C</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>metastatic castration-resistant prostate cancer</keyword>
	<keyword>enzalutamide</keyword>
	<keyword>LY2157299</keyword>
	<keyword>TGF-β receptor inhibitor</keyword>
</DOC>